— Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs —
— Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to continue as strategic partnering options are pursued —
— Cost restructuring plan reduces San Francisco-based workforce by approximately 60% and extends cash runway into the middle of 2026 —
— Company to announce financial results for the first quarter of 2023 after close of U.S.-based financial markets on May 9, 2023 —
SAN FRANCISCO, April 17, 2023 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as sever…
Read the full article at: https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-strategic-reprioritization-and-cost-restructuring-plan-301799422.html